The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own

The next wave of AI adoption is shifting from tool-builders to companies applying AI in real-world drug development. Eli Lilly leverages AI partnerships with OpenAI and Nvidia for drug discovery while expanding its weight-loss portfolio, showing strong financial growth. Twist Bioscience supplies synthetic DNA for drug testing and benefits from Amazon's new Bio Discovery platform, offering higher-risk growth potential.